Are You Ignoring This Predictive Stock Indicator?
Everyone makes money in investing by following a trend.
Whether your time horizon is minutes or months, a financial instrument must move in your favor to be profitable. It is that simple. So finding an indicator to measure trend is critical to your success.
There’s a simple, quantitative indicator we use to find stocks with the propensity for a big move… It’s called relative strength (RS).
What Is Relative Strength (RS)?
Relative strength investing is pretty straightforward. It involves buying the best-performing stocks relative to all other stocks. We then hold these stocks until their momentum changes course.
To most investors, especially “value-minded” investors, this strategy probably feels counterintuitive. After all, one of the first things you learn as an investor is to “buy low, sell high.”
But what we feel and what we can prove are two very different things. And there are decades of research to prove the predictive power of this indicator.
In the 1950s, George Chestnutt created one of the first newsletters using RS to rank stocks and industry groups. He also used RS to manage the successful American Investors Fund. This fund produced a cumulative return of 160% between 1958 and 1964, compared with 83% for the Dow.
In the late 1960s, Robert Levy published a study in the Journal of Finance discussing the direct correlation between the percentile ranking of RS and the performance of a stock over the next six months. He found that, in general, the higher a stock’s RS, the better its performance. It was groundbreaking for the time.
Levy planted a seed, and RS became the topic of numerous studies and papers over the ensuing decades. One of the most famous academic studies on RS was completed in 1993 by Narasimhan Jegadeesh and Sheridan Titman.
Their oft-cited study covered the 24-year period from 1965 to 1989. It clearly demonstrated that buying past high-performing stocks and selling low-performing stocks made significantly abnormal positive returns. More specifically, they found that buying stocks based on high past six-month returns and holding them for the next six months beat the market by an average of 12% a year.
In other words, a momentum-based strategy works.
In 2013, Christopher Geczy and Mikhail Samonov published “212 Years of Price Momentum — The World’s Longest Backtest: 1801-2012.” It showed there was a positive and statistically significant correlation between momentum and stock performance going back to the start of the 19th century.
A primary reason RS works is that stocks produce skewed, excess positive and negative returns. In other words, they do not follow the standard bell-shaped performance curve, which is strikingly obvious when you overlay the two.
Perhaps the most striking difference is at the ends of each chart. The bar chart representing the 10-year returns for individual S&P 500 companies has “fat tails” — high bars at both ends of the graph. This shows show there are just as many, if not more, companies with extreme high and low returns as there are companies with average returns.
Based on the normal bell curve, this isn’t supposed to happen. Yet it does because stock returns are not normally distributed.
How We Use RS
A stock’s RS can range from 0 (weakest) to 100 (strongest). We only consider buying stocks with a RS above 70 — and typically a good deal higher than that.
However, to be transparent, price momentum isn’t the only thing that we use to determine buys and sells. And it shouldn’t be the sole determinant you use, either.
The picks for our Maximum Profit system, for example, are also based on the relative strength of a key fundamental measure. In other words, we look at how this fundamental measure stacks up against every other publicly traded company. And like relative strength, we rank it on a scale from 0 to 100.
When this rank is combined with price RS, we calculate an average between the two scores. Again, based on a 0 to 100 scale, the predicative power of this combined indicator is unparalleled with anything we have ever come across.
To this end, we are protective of the indicator. Because the fewer people who know about it, the greater the edge. But we periodically open up our playbook and reveal exactly how this predictive tool works — but only to a few hundred readers at a time. If you’d like to be one of them, simply tell us you’d like to be put on the Maximum Profit “waitlist” here.
P.S. Do you know the most common health problem that afflicts older Americans? It’s not cancer, Alzheimer’s, or diabetes… It’s chronic pain.
One in five Americans suffer from pain that resists conventional treatment. And until recently, all existing treatments had harmful side effects (like addiction). But one biotechnology company has developed a new addiction-free cure… And its stock price is primed to take off.
You’ve probably never heard of the company. Wall Street analysts are ignoring it. But our investment experts have uncovered this hidden biotech gem — and they say now’s the time to invest. Go here to learn more.